Medtronic unveiled three new additions to its coronary portfolio Monday—a transradial diagnostic catheter and accompanying transradial devices to facilitate the treatment of coronary artery disease via the radial artery in the wrist.
Percutaneous coronary intervention, or PCI, is a nonsurgical procedure to treat the narrowing of coronary arteries. While PCI usually involves balloon angioplasty to compress plaque against the wall of the artery, the physician may also deploy a stent to keep the artery open. It is usually done through the femoral artery or the radial artery.
Medtronic announced Monday that it was launching the DxTerity Diagnostic Angiography Catheter line and a suite of transradial products, including an access kit and compression device.
The diagnostic catheters are used to ascertain whether a patient will need revascularization—bypass or angioplasty—to treat their coronary artery disease. Meanwhile, the InTRAkit access kit includes components such as ergonomic needles and tapered introducer sheaths to improve the transradial procedure. The TRAcelet compression device simplifies pressure control at the access site.
"The global approval of the DxTerity Diagnostic Catheters, as well as the introduction of the new Medtronic suite of transradial products represents a significant step forward for patients requiring PCI procedures," said Dr. Sunil Rao, an interventional cardiologist and associate professor of medicine at Duke University, in the statement. "It's increasingly important to have a full suite of products accompanied by robust training to increase physician utilization, improve patient comfort and enable same-day discharge."
The devicemaker is also launching in the U.S. an education and training tool for physicians, staff and administrators dubbed the Transradial Arc Curriculum. It is designed to provide clinical training to help hospitals improve their delivery of transradial care, Medtronic said.
"Our new line of comprehensive transradial products and programs that support PCI from start to finish were developed to meet the evolving clinical and health economic needs of physicians, administrators and cath lab teams around the globe," said Jason Weidman, vice president and general manager of Medtronic’s coronary and renal denervation business, in the statement. "Our intent with these recent innovations in our premium product portfolio is to help accelerate adoption of the transradial approach so that more patients and hospitals may experience the advantages transradial access can bring."